Tetrahydrobiopterin and Autism Spectrum Disorder
- Definition and Clinical Features:
- Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by persistent deficits in three key domains:
- Social interaction
- Communication
- Repetitive and restricted behaviors
- Epidemiology:
- United States prevalence:
- 17 cases per 1000 children aged 4 years
- 18.5 cases per 1000 children aged 8 years
- Europe prevalence:
- Ranges from 3.8 to 15.5 cases per 1000 individuals
- Actual prevalence may be underestimated due to:
- Diagnostic challenges
- Lack of reliable, sensitive, and specific biomarkers
- Pathogenesis:
- The exact etiology of ASD is multifactorial, involving:
- Genetic predisposition
- Environmental influences
- Persistent inflammatory states
- Immune dysregulation
- Genetic factors include:
- Mutations and polymorphisms in genes regulating synaptic function, neurotransmitter pathways, and immune responses
- Neurobiological characteristics of ASD:
- Abnormal synaptic connectivity
- Imbalance in excitatory–inhibitory signaling
- Dysregulation in neurotransmitter systems, including:
- Serotonin
- Dopamine
- Glutamate
- Gamma-aminobutyric acid (GABA)
- Other critical factors implicated include:
- Immune dysfunction and chronic inflammation
- Oxidative stress
- Metabolic abnormalities, notably mitochondrial dysfunction
- Role of tetrahydrobiopterin (BH4):
- Many implicated molecular and signaling pathways depend on the availability of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)
- Alterations in BH4 metabolism may significantly contribute to the pathogenesis of ASD
To read more, a subscription is needed: Click here to subscribe